Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 9/20 | 0.61 |
| ▸ | REN | P00797 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2441754 | 1.00 | ACE (0.61) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL31285433 | 1.00 | ACE (0.61) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL5743561 | 1.00 | ACE (0.61) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL2441752 | 1.00 | ACE (0.61) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL6039783 | 1.00 | ACE (0.61) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL5743553 | 1.00 | ACE (0.61) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL6791984 | 1.00 | ACE (0.61) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL14484393 | 0.94 | ACE (0.59) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL27285049 | 0.94 | ACE (0.62) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL21163968 | 0.92 | ACE (0.57) | ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0915088-B1 | D-Proline derivatives | HOFFMANN LA ROCHE (CH) | 2002-09-18 | — | — | EP | claimed |
| US-6103910-A | FOR TREATMENT OF DISEASES ASSOCIATED WITH AMYLOIDOSIS, SUCH AS ALZHEIMER'S DISEASE, DIABETES MELLITUS, FAMILIAL AMYLOID POLYNEUROPATHY, SCRAPIE, AND KREUZFELD-JACOB DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2000-08-15 | — | — | US | claimed |
| EP-0915088-A1 | D-Proline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-05-12 | — | — | EP | claimed |
| EP-1633345-B1 | COMPOUNDS INHIBITING THE BINDING OF SAP FOR TREATING OSTEOARTHRITIS | PENTRAXIN THERAPEUTICS LTD (GB) | 2011-09-21 | — | — | EP | disclosed |
| US-7659299-B2 | Substituted or unsubstituted D-proline or stereoanalogue (R)-1-[6(R)-2-Carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid; inhibit serum amyloid P (SAP) ligand binding activity or depleting SAP from the plasma of the subject; avoid potentially harmful pro-inflammatory effects | PENTRAXIN THERAPEUTICS LIMITED (GB) | 2010-02-09 | — | — | US | disclosed |
| US-20080249003-A1 | Compounds Inhibiting the Binding of Sap for Treating Osteoarthritis | PENTRAXIN THERAPEUTICS LIMITED (GB) | 2008-10-09 | — | — | US | disclosed |
| US-6740760-B2 | SUCH AS 1-((S)-3-MERCAPTO-2-METHYL-PROPIONYL)-(R)-PYRROL-IDINE-2-CARBOXYLIC ACID FOR TREATING DISEASES ASSOCIATED WITH AMYLOIDOSIS (ALZHEIMER'S DISEASE, DIABETES, AND FAMILIAL AMYLOID POLYNEUROPATHY) | HOFFMANN-LA ROCHE INC. | 2004-05-25 | — | — | US | disclosed |
| US-20030100770-A1 | Such as 1-((S)-3-mercapto-2-methyl-propionyl)-(R)-pyrrol-idine-2-carboxylic acid for treating diseases associated with amyloidosis (Alzheimer's disease, diabetes, and familial amyloid polyneuropathy) | PENTRAXIN THERAPEUTICS LTD. (GB) | 2003-05-29 | — | — | US | disclosed |
| US-6512001-B1 | To treat diseases associated with amyloidosis, such as Alzheimer's disease | HOFFMANN-LA ROCHE INC. | 2003-01-28 | — | — | US | disclosed |
| EP-0915088-B1 | D-Proline derivatives | HOFFMANN LA ROCHE (CH) | 2002-09-18 | — | — | EP | disclosed |
| US-6262089-B1 | USING THESE COMPOUNDS TO TREAT DISEASES ASSOCIATED WITH AMYLOIDOSIS, SUCH AS ALZHEIMER'S DISEASE, MATURITY ONSET DIABETES MELLITUS, FAMILIAL AMYLOID POLYNEUROPATHY, SCRAPIE, AND KREUZFELD-JACOB DISEASE. | HOFFMAN-LA ROCHE INC. | 2001-07-17 | — | — | US | disclosed |
| US-6103910-A | FOR TREATMENT OF DISEASES ASSOCIATED WITH AMYLOIDOSIS, SUCH AS ALZHEIMER'S DISEASE, DIABETES MELLITUS, FAMILIAL AMYLOID POLYNEUROPATHY, SCRAPIE, AND KREUZFELD-JACOB DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2000-08-15 | — | — | US | disclosed |
| EP-0915088-A1 | D-Proline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100770-A1 | Such as 1-((S)-3-mercapto-2-methyl-propionyl)-(R)-pyrrol-idine-2-carboxylic acid for treating diseases associated with amyloidosis (Alzheimer's disease, diabetes, and familial amyloid polyneuropathy) | PSEN1, PSEN2, IAPP | ACE 1460/4885REN 166/4885LMNA 2616/4885 |
| US-20080249003-A1 | Compounds Inhibiting the Binding of Sap for Treating Osteoarthritis | SAP30BP, SYVN1, SERPINB1 | ACE 1249/4885REN 3332/4885LMNA 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.